|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 209/94 | (2006.01) |
| C07D 209/94 | (2013.01) | ||
| A61K 31/403 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 17/02 | (2018.01) | ||
| A61P 17/06 | (2018.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 17/10 | (2018.01) | ||
| A61P 7/00 | (2006.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 3/00 | (2006.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 5/00 | (2006.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 37/00 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 5/00 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 3/10 | (2018.01) | ||
| C07C 279/14 | (2013.01) |
| (11) | Number of the document | 3310760 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16734529.7 |
| Date of filing the European patent application | 2016-06-21 | |
| (97) | Date of publication of the European application | 2018-04-25 |
| (45) | Date of publication and mention of the grant of the patent | 2022-09-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/038506 |
| Date | 2016-06-21 |
| (87) | Number | WO 2016/209809 |
| Date | 2016-12-29 |
| (30) | Number | Date | Country code |
| 201562182841 P | 2015-06-22 | US | |
| 201562207531 P | 2015-08-20 | US |
| (72) |
BLACKBURN, Anthony C. , US
CASTRO, Ryan O. , US
HADD, Mark A. , US
MA, You-An , US
MONTALBAN, Antonio Garrido , US
RUETER, Jaimie Karyn , US
SELVEY, Lee Alani , US
SHAKYA, Sagar Raj , US
CARLOS, Marlon , US
|
| (73) |
Arena Pharmaceuticals, Inc. ,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS |
| CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS |